
For companies that are prepared, Part D represents a great opportunity. For others, failing to react quickly enough could be a costly mistake.


For companies that are prepared, Part D represents a great opportunity. For others, failing to react quickly enough could be a costly mistake.

One response to today's safety concerns is particularly alarming: The research community has become skittish about conducting clinical studies involving pain medications and other high-risk treatments.